For U.S. Healthcare Professionals Only
+|Aa|-
Product Access

What are patients paying for their Renvela® prescriptions?

  • According to a survey of over 165,000 dialysis patients, 7 in 10 patients pay $8/month or less for Renvela.1
    • Over 55% of patients, most of whom have Medicare and Medicaid, pay <$8/month.
    • Another 15% of patients with commercial prescription insurance pay $5/month with the RenValueâ„  copay card program.1
  • Renassist® case managers can help identify Renvela reimbursement solutions for patients with or without prescription coverage. Learn more at Renassist.com or call 1-800-847-0069 to speak with your regional case manager.

Where do your patients fit in?

The national distribution of prescription drug coverage for dialysis patients is depicted in the chart below.1

Prescription drug coverage mixa (n=165,000)

Affordability Affordability

a Data from DaVita Rx Profiles, August 2015.

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.

Please see additional Important Safety Information.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®

Renvela is a preferred medication on the majority of our nation's commercial drug plans.1

Learn more at Renassist.com.

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Reference:

  1. Data on file, Sanofi US.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients. Click here to read more.